treatment of milademetan versus trabectedin in patient with dedifferentiated liposarcoma

Conditions: Dedifferentiated Liposarcoma

Summary: randomized, multicenter, open-label, phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic dd liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

approximately 160 patients will be randomly assigned in a 1:1 ratio to receive milademetan or trabectedin. randomization will be stratified by the ecog performance status (0 or 1) and number of prior treatments (≤ 2 or \> 2) for the patient's liposarcoma. patients will receive study drug (i.e., milademetan or trabectedin) until reaching unequivocal disease progression (recist v.1.1) as determined by the investigator, experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. patients may be treated beyond tumor progression if they are experiencing clinical benefit based on the assessment of the investigator in discussion with the medical monitor. all patients will be followed for documentation of disease progression and survival information (i.e., date and cause of death) and subsequent treatment information (i.e., date/duration of treatment, response, and subsequent disease progression). long-term follow-up will continue every 12 weeks (± 7 days) until the endpoint of death, the patient is lost to follow-up, or for 24 months following the final dose of study drug, whichever comes first.

Eligibility criteria:
inclusion criteria: * histologically confirmed dd liposarcoma, with or without a wd component (wd/dd liposarcoma). note: patient must be willing to provide an archival tumor tissue sample that is ≤ 3 years old and of adequate quality or willing to provide a fresh pretreatment biopsy sample * advanced unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) and/or metastatic wd/dd liposarcoma * measurable tumor lesion(s) in accordance with recist version 1.1 * received 1 or more systemic cancer therapy regimens, including at least 1 anthracycline-based regimen, and had radiographic progressive disease (per recist version 1.1) within 6 months before the screening visit * resolution of any clinically relevant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy * ecog performance status of 0 or 1 * adequate bone marrow function: * platelet count ≥ 100 × 10\^9/l * hemoglobin ≥ 9.0 g/dl * absolute neutrophil count ≥ 1.5 × 10\^9/l * adequate hepatic function: * alanine aminotransferase and aspartate aminotransferase ≤ 3 × upper limit of normal (uln) if no liver metastases are present; ≤ 5 × uln if liver metastases are present * total bilirubin ≤ 1.5 × uln, or ≤ 3 x uln in the setting of gilbert's disease exclusion criteria: * prior treatment with any mouse double minute 2 (mdm2) inhibitor or trabectedin * other primary malignancies that have required systemic antineoplastic treatment within the previous 2 years, except for localized cancers that have apparently been cured * gastrointestinal conditions that could affect the absorption of milademetan, in the opinion of the investigator * uncontrolled infection within the last 7 days requiring iv antibiotics, antivirals, or antifungals * known hiv infection or active hepatitis b or c * untreated brain metastases. note: patients who require steroids for brain metastases must be on a stable or tapering dose of corticosteroids for at least 2 weeks before randomization. if applicable, patients must complete stereotactic radiosurgery 7 days before and whole brain radiotherapy 21 days before their first dose of study drug. * investigational therapy administered within the 28 days or 5 half lives: 1. cytochrome p450 3a4 isozyme strong inhibitor: 5 elimination half-lives 2. cyp3a strong or moderate inducers: 4 weeks 3. systemic anticancer therapy or investigational therapy 3 weeks or 5 half-lives, 4. immunotherapy with checkpoint inhibitor: 4 weeks * curative-intent radiation therapy ≤ 4 weeks or palliative radiation therapy, * uncontrolled or significant cardiovascular disease: 1. qtcf at rest, where the mean qtcf interval is \> 480 milliseconds 2. myocardial infarction within 6 months 3. uncontrolled angina pectoris within 6 months 4. new york heart association class 3 or 4 congestive heart failure 5. uncontrolled hypertension

Keywords: sarcoma mdm2 pleomorphic liposarcoma